Fixed-Duration Ibrutinib Plus Venetoclax Shows Long-Term Efficacy in First-Line CLL/SLL Treatment

Source: Pharmacy Times articles

Ibrutinib plus venetoclax shows promising long-term survival rates, including those who are considered high risk.
Read More